| Document |
Document Title |
|
WO/2019/241751A1 |
Described herein are compounds that are semicarbazide-sensitive amine oxidase (SSAO) inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds...
|
|
WO/2019/238867A1 |
The present disclosure generally relates to herbicidal compositions, and more particularly, herbicidal compositions containing glyphosate or a salt thereof and a surfactant comprising at least one castor oil triglycidyl ether-based ("COT...
|
|
WO/2019/240840A1 |
Provided herein are silicon-containing recyclable polyamino compounds; epoxy compositions containing these silicon-containing reworkable or recyclable polyamino compounds; and methods of their use.
|
|
WO/2019/240058A1 |
Provided are: a fullerene compound; a lubricant that is for a magnetic recording medium and that contains the fullerene compound; and a magnetic recording medium. The fullerene compound according to the present invention is characterized...
|
|
WO/2019/240841A1 |
This application relates, in part, to novel salts represented by the following structure of Formula (1), wherein R1a is selected from the group consisting of hydrogen and optionally substituted alkyl (e.g., unsubstituted C1-6 alkyl, e.g....
|
|
WO/2019/234405A1 |
The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of For...
|
|
WO/2019/232180A1 |
A cationic surfactant and a method of making the cationic surfactant are described. The method comprises reacting a lipophilic bio-based material having at least one epoxy functional group and a hydrophilic organic compound having at lea...
|
|
WO/2019/218902A1 |
The present invention relates to a perfluoropolyether compound which contains a carboxyl group as shown in by formula (I). In the forumula Rf-X1-X2(I), Rf represents F-(CF2)m-(OC4F8)p-(OC3F6)q-(OC2F4)r-(OCF2)s-OC(Z)F-(CF 2)n-, wherein p,...
|
|
WO/2019/219942A1 |
Provided is a process for producing an amine via a hydroaminoalkylation reaction of a non-aromatic C-C double bond or C-C triple bond, said process comprising a step of reacting a compound comprising a non-aromatic C-C double bond or C-C...
|
|
WO/2019/209182A1 |
Disclosed herein are compounds of formula I, where said compounds displays antibacterial properties. Also disclosed herein is the use of said compounds to treat microbial infection. The compounds of formula I have the following structure...
|
|
WO/2019/197232A1 |
The invention relates to a multi-stage process for producing 2,6-dialkylphenyl acetic acids of general formula (I) by reacting 2,6-dialkyl bromobenzenes with (1) magnesium, (2) a formamide, (3) an acid, (4) hydrogenation of the benzaldeh...
|
|
WO/2019/198023A1 |
Subject-matter of the present invention is a process for the preparation of optically active phenyl-beta-amino alcohols by means of a specific reduction of the corresponding phenyl-beta-amino ketones. Further subject-matter of the invent...
|
|
WO/2019/196263A1 |
The present invention relates to the field of pharmaceutical synthesis, in particular to a method for preparing a hexahydrofuro-furanol derivative, an intermediate thereof and a preparation method therefor. The preparation method compris...
|
|
WO/2019/199863A1 |
Provided are compounds, or pharmaceutically acceptable salts thereof, which are useful for inhibiting FOXM1, inhibiting cancer growth, and/or treating cancer. In particular, these compounds and their corresponding quaternary ammonium sal...
|
|
WO/2019/191624A1 |
The present invention includes substituted 3,3'-bis(phenoxymethyl)-1,1'-biphenyl compounds, analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (H...
|
|
WO/2019/190172A1 |
The present invention is to provide a compound represented by the formula 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same, which can be used for preventing or treating obesity or meta...
|
|
WO/2019/181714A1 |
A compound according to the present invention is characterized by being represented by formula wherein: R1 represents an oxygen atom or a sulfur atom; and each of R2-R6 independently represents a hydrogen atom, an alkyl group having 1-6 ...
|
|
WO/2019/175352A1 |
The current invention relates to long α-ω di-functional linear molecules as building blocks closing the gap between small molecules and polymers, or in a polycondensated form, in the production of oligomers and/or polymers, surfactants...
|
|
WO/2019/175897A1 |
The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tau...
|
|
WO/2019/169402A1 |
Apparatus and a method for cleaning accumulated sediment from storm drain conduits and other large-diameter conduits. A nozzle assembly is arranged to deliver a high-volume flow of water at a pressure high enough to loosen sediment from ...
|
|
WO/2019/166578A1 |
The present invention relates to the field of catalytic hydrogenation and to the use of ruthenium complexes having a bidentate diphosphine ligand or two monodentate phosphine ligands, two carboxylate ligands and optionally a diamine liga...
|
|
WO/2019/162121A1 |
The invention relates to a method for the continuous separation by distillation of mixtures containing morpholine (MO), monoaminodiglycol (ADG), ammonia, water and methoxyethanol (MOE), obtained by reacting diethylene glycol (DEG) with a...
|
|
WO/2019/153216A1 |
The present invention relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. In the formula (I), Ar is an aryl group, a heteroaryl group, or an aryl or heteroaryl group substituted by one or mo...
|
|
WO/2019/155169A1 |
The present invention relates to difunctional biphenyl compounds according to formula (I): in which Alk, Alk' and R are as defined in the description. Said compounds are suitable for use as curing agents for thermosetting resins, particu...
|
|
WO/2019/137724A1 |
The present invention relates to ureylene additives, a method for their preparation, a use of said ureylene additives favorably as additive in metal or metal alloy deposition composition, preferably in a copper or copper alloy deposition...
|
|
WO/2019/127920A1 |
A liquid phase spherical carrier as represented by formula I, a preparation method therefor and use thereof. R is a functional group, preferably a group having hydroxyl, amino, carboxyl or halogen. The liquid phase synthesis carrier can ...
|
|
WO/2019/088800A9 |
The present invention relates to a polyethylene glycol derivative and a preparation method thereof. A preparation process of a polyethylene glycol derivative, according to the present invention, may provide a novel polyethylene glycol de...
|
|
WO/2019/107533A1 |
The present invention provides a compound for suppressing cell transformation, the compound being represented by the following general formula (wherein n is 1 or 2; R1 is H, methoxy(-OCH3), or Cl; R2 is H, -OCH3, or Cl; R3 is H, -OCH3, C...
|
|
WO/2019/106084A1 |
Disclosed is a continuous process for the oxidation of tertiary amines to provide an amine oxide composition.The process involves mixing a tertiary amine and an aqueous oxidizing agent in a spinning disk reactor and (1) diluting and/or d...
|
|
WO/2019/103989A1 |
Pharmaceutical compositions of the invention comprise functionalized N,N-dialkylamino phenyl ethers derivatives having a disease-modifying action in the treatment of diseases associated with lysosomal storage dysfunction that include Gau...
|
|
WO/2019/103639A1 |
The invention relates to the field of protecting metals from corrosion in the oil and gas industry during the production, storage, and transport of hydrocarbons, and can be used for protecting parts of engines that run on a hydrocarbon f...
|
|
WO/2019/076904A1 |
The application relates to compounds of formula (I) that show great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels or dual activi...
|
|
WO/2019/071348A1 |
There is provide an extended release dosage form comprising a release modifying excipient comprising high amylose starch, cross-linked hydroxypropylated amylopectin, and a pre-gelatinized common starch; wherein the release modifying exci...
|
|
WO/2019/066337A1 |
The present specification relates to a compound represented by chemical formula (1), a coating composition comprising the compound represented by chemical formula (1), an organic light-emitting diode using same, and a method for preparin...
|
|
WO/2019/066338A1 |
The present specification relates to a coating composition, an organic light-emitting diode using same and a method for preparing same. The coating composition comprises: a compound represented by chemical formula (1); and an ionic compo...
|
|
WO/2019/063952A1 |
The invention relates to a new method for the synthesis of unsymmetrical tertiary amines using alcohol and an imine, and to new tertiary amines.
|
|
WO/2019/053494A1 |
The present invention relates to a process of preparation of O-Desmethyl tramadol through potassium hydroxide mediated demethylation of Tramadol under phase transfer conditions.
|
|
WO/2019/051222A1 |
The present disclosure provides a benzene fused heterocyclic derivative of Formula (I): --̅-̅-̅ is a single or double bond; n is an integer of 0 or 1; A is -CH2-, -CH(OH)-, or - C(O)-; G is C or N; X is -CH2-, O, or -C(O)-; Y is alkyl...
|
|
WO/2019/051416A1 |
The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifin, and compositions comprising them. The present disclosure also provides methods for treating hormone-...
|
|
WO/2019/035775A1 |
A method for the preparation of tapentadol in the form of a base or its hydrogen chloride, which involves the preparation of a salt (III) from a mixture of diastereomers (II) by means of crystallization-induced asymmetric transformation ...
|
|
WO/2019/032743A1 |
The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
|
|
WO/2019/024924A1 |
The present invention relates to an amine compound for inhibiting semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitors and use thereof in medicine, and further relates to a pharmaceutical com...
|
|
WO/2019/022251A1 |
A (poly)amine compound represented by formula (0): (in formula (0), RX represents a C1-70 2nA-valent group or a single bond; R1A each independently represent an optionally substituted C1-30 alkyl group, an optionally substituted C6-30 ar...
|
|
WO/2019/020026A1 |
Disclosed are a difluoromethoxy diphenylethane and trans-stilbene derivatives, and a preparation method therefor and the use thereof. The present invention conducts a chemical structure modification with a difluoromethoxy group at the 4'...
|
|
WO/2019/018785A2 |
Compounds, pharmaceutical compositions, and methods for treating cancer, in particular brain cancer, are provided, including amphiphilic fatty acid/alcohol ethers (AIPs) comprising endocannabinoid and FABP motifs covalently linked to a b...
|
|
WO/2019/016512A1 |
The present invention relates to an amorphous form of vilanterol trifenatate, processes for its preparation and its use in pharmaceutical formulations for the treatment of respiratory diseases, particularly for the treatment of asthma an...
|
|
WO/2019/016511A2 |
The present invention relates to new crystalline forms of vilanterol trifenatate, processes for their preparation, and their use in a pharmaceutical composition for the treatment of respiratory diseases, particularly for the treatment of...
|
|
WO/2019/013299A1 |
The present invention provides a thermally conductive material that has excellent thermal conductivity. The present invention also provides: a device that is provided with a thermally conductive layer that includes the thermally conducti...
|
|
WO/2019/009412A1 |
The present invention addresses the problem of providing a novel compound having high LSD1 inhibitory activity, high selectivity for LSD1 inhibition, and/or having useful therapeutic effects for various diseases. One embodiment of the pr...
|
|
WO/2019/008156A1 |
The present invention provides novel compounds of formula (I) that are useful as inhibitors of the PD-1/PD-L1 protein/protein interaction. The compounds may be used in the treatment of cancer, infectious diseases and neurodegenerative di...
|
